IPM 027/ The Ring Study

Principal Investigator(s):
Objective:A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women To assess the safety and efficacy of a silicone elastomer vaginal matrix ring. Results summary: The Ring Study reported results early in February 2016 after an independent safety and monitoring board recommended the study proceed to final analysis. It has moved to open-label in South Africa and Uganda. In July, 2016 new analyses announced by MTN at AIDS 2016 found that, among women who appeared to use the monthly ring consistently, HIV risk was cut by at least 56 percent — a statistically significant finding. Last updated September 23, 2022
Prevention Option(s):Microbicides
Study Design:Controlled, Double-blind, Placebo, Randomized
Arms and Assigned Interventions
DescriptionVaginal ring containing 25mg dapivirine; one ring inserted once every 4 weeks over 24 months.
Mode of DeliveryRing
Official Code: NCT01539226
Trial Sponsors: International Partnership for Microbicides
Start Date
End Date
April 30, 2012
December 31, 2016
Age range: 18 Years ↔ 45 Years
Population:Cisgender Women